Prostatype Genomics AB (OSTO:PROGEN) Operating Cash Flow per Share : kr-0.32 (TTM As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Prostatype Genomics AB Operating Cash Flow per Share?

Prostatype Genomics AB's operating cash flow per share for the three months ended in Jun. 2023 was kr-0.06. Prostatype Genomics AB's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2023 was kr-0.32.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -17.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Prostatype Genomics AB's Operating Cash Flow per Share or its related term are showing as below:

OSTO:PROGEN' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -125.9 Med: -71.75 Max: -17.6
Current: -17.6

During the past 5 years, Prostatype Genomics AB's highest 3-Year average Operating Cash Flow per Share Growth Rate was -17.60% per year. The lowest was -125.90% per year. And the median was -71.75% per year.

OSTO:PROGEN's 3-Year OCF Growth Rate is ranked worse than
73.6% of 178 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.4 vs OSTO:PROGEN: -17.60

Prostatype Genomics AB Operating Cash Flow per Share Historical Data

The historical data trend for Prostatype Genomics AB's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB Operating Cash Flow per Share Chart

Prostatype Genomics AB Annual Data

Trend

Jun18

Jun19

Dec21

Dec22

Dec23

Operating Cash Flow per Share

-0.13

-0.22

-0.23

-1.52

-0.36

Prostatype Genomics AB Quarterly Data
	Jun18	Jun19	Mar20	Jun20	Sep20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial											-0.10	-0.07	-0.09	-0.06	-

Competitive Comparison of Prostatype Genomics AB's Operating Cash Flow per Share

For the Diagnostics & Research subindustry, Prostatype Genomics AB's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prostatype Genomics AB's Price-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Prostatype Genomics AB's Price-to-Operating-Cash-Flow falls into.

Prostatype Genomics AB Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Prostatype Genomics AB's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-29.138	/	80.820
	=	-0.36

Prostatype Genomics AB's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Jun. 2023 )	=	Cash Flow from Operations (Q: Jun. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Jun. 2023 )
	=	-11.061	/	185.390
	=	-0.06

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.32

Prostatype Genomics AB Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Prostatype Genomics AB (OSTO:PROGEN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (OSTO:PROGEN) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

PGO:Germany

Address

Gustaf III:s Boulevard 34, Solna, SWE, 169 73

Website

https://www.prostatypegenomics.com

Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB (OSTO:PROGEN) Headlines

No Headlines